152 related articles for article (PubMed ID: 10418899)
1. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice.
Jones CD; Page M; Bacon A; Cahill E; Bentley M; Chatfield SN
Vaccine; 1999 Jun; 17(20-21):2528-37. PubMed ID: 10418899
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene); evidence for superior anti-SHBs antibody induction in responder mice.
Jones CD; Page M; Bacon A; Cahill E; Bentley M; Chatfield SN
J Viral Hepat; 1998 Nov; 5 Suppl 2():5-8. PubMed ID: 9857353
[TBL] [Abstract][Full Text] [Related]
3. A novel, recombinant triple antigen hepatitis B vaccine (Hepacare).
Page M; Jones CD; Bailey C
Intervirology; 2001; 44(2-3):88-97. PubMed ID: 11509870
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene products.
Pride MW; Bailey CR; Muchmore E; Thanavala Y
Vaccine; 1998 Apr; 16(6):543-50. PubMed ID: 9569463
[TBL] [Abstract][Full Text] [Related]
5. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines.
Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH
Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine.
McDermott AB; Cohen SB; Zuckerman JN; Madrigal JA
Vaccine; 1999 Jan; 17(4):330-9. PubMed ID: 9987171
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
Raz R; Koren R; Bass D
Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a new type of yeast-derived hepatitis B vaccine consisting of M (pre-S2 + S) protein particles.
Hazama M; Takaoki M; Ohfune K; Hinuma S; Fujisawa Y
Vaccine; 1989 Dec; 7(6):567-73. PubMed ID: 2532813
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.
Niedre-Otomere B; Bogdanova A; Skrastina D; Zajakina A; Bruvere R; Ose V; Gerlich WH; Garoff H; Pumpens P; Glebe D; Kozlovska T
J Viral Hepat; 2012 Sep; 19(9):664-73. PubMed ID: 22863271
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen.
Douvin C; Simon D; Charles MA; Deforges L; Bierling P; Lehner V; Budkowska A; Dhumeaux D
Diabetes Care; 1997 Feb; 20(2):148-51. PubMed ID: 9118762
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--evidence for genetic basis in humans.
McDermott AB; Cohen SB; Zuckerman JN; Madrigal JA
J Viral Hepat; 1998 Nov; 5 Suppl 2():9-11. PubMed ID: 9857354
[TBL] [Abstract][Full Text] [Related]
13. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
[TBL] [Abstract][Full Text] [Related]
14. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults.
Eyigün CP; Yilmaz S; Gül C; Sengül A; Hacibektasoglu A; Van Thiel DH
J Viral Hepat; 1998 Jul; 5(4):265-9. PubMed ID: 9751013
[TBL] [Abstract][Full Text] [Related]
15. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses.
Bian G; Cheng Y; Wang Z; Hu Y; Zhang X; Wu M; Chen Z; Shi B; Sun S; Shen Y; Chen EJ; Yao X; Wen Y; Yuan Z
Vaccine; 2009 Dec; 28(1):187-94. PubMed ID: 19789093
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a 'pre-S2 plus S' hepatitis B vaccine in healthy adults.
Katkov WN; Watkins E; DeMelia HC; Dienstag JL
J Viral Hepat; 1994; 1(1):79-83. PubMed ID: 8790563
[TBL] [Abstract][Full Text] [Related]
17. [Antibody responses in human being to pre-S2 and related hepatitis B virus-envelope antigens in vivo and in vitro].
Ogata M; Ishikawa H; Kato Y; Honta S; Yoshida H; Yasuda H; Ohto H; Watanabe N
Rinsho Byori; 1991 Jan; 39(1):3-13. PubMed ID: 1826138
[TBL] [Abstract][Full Text] [Related]
18. A study of the antigenicity and immunogenicity of a new hepatitis B vaccine using a panel of monoclonal antibodies.
Waters JA; Bailey C; Love C; Thomas HC
J Med Virol; 1998 Jan; 54(1):1-6. PubMed ID: 9443102
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein.
Yamada T; Iwabuki H; Kanno T; Tanaka H; Kawai T; Fukuda H; Kondo A; Seno M; Tanizawa K; Kuroda S
Vaccine; 2001 Apr; 19(23-24):3154-63. PubMed ID: 11312011
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
